Prostate Cancer Genomics - Cancer PHGKB -

Specific PHGKB|Cancer|PHGKB

Prostate Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Aug 30, 2018

---

• NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: © NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.  
  et al. BJU international 2018 Aug 122(2) 173-180
• PRODIGE: PRediction models in prOstate cancer for personalized meDIcine challenGE.  
  Alitto A R et al. Future oncology (London, England) 2017 Oct 13(24) 2171-2181
• The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. 
  Bramhecha Yogesh M et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Aug
• Systematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome.  
  Huang Dora et al. Bladder cancer (Amsterdam, Netherlands) 2018 Jul 4(3) 261-268
• Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Required)  
  NCI Moonshot Funding Announcement, August 10, 2018
• Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.  
  Bismar Tarek A et al. Journal of cancer research and clinical oncology 2018 Aug
• Medically underserved women in the Southeast rarely receive BRCA tests  
  VUMC Reporter, August 14, 2018
• The role of genomics in patients with advanced prostate cancer.  
  Hussain Maha H et al. Clinical advances in hematology & oncology : H&O 2017 Oct 15(10) 770-772
• Breast cancer and men: Gene mutations that contribute to risk can also signal prostate, pancreatic cancers  
  M Erickson, Star News Online, August 6, 2018
• Genomic biomarkers in prostate cancer.  
  Kornberg Zachary et al. Translational andrology and urology 2018 Jun 7(3) 459-471